CervoMed Inc. (CRVO), a clinical-stage biopharmaceutical company, on Wednesday announced that investigators will present results from the Phase 2b RewinD-LB study demonstrating that neflamapimod slows clinical progression in Dementia with Lewy Bodies or DLB at the AD/PD 2025 conference on April 5, 2025.
The study's 16-week Extension phase showed that neflamapimod led to improvements in cognitive and motor function, with a clinically meaningful reduction in disease progression compared to controls, as measured by CDR-SB (Clinical Dementia Rating Sum of Boxes) and CGIC (Clinical Global Impression of Change).
Patients receiving the New Capsules, which achieved target plasma drug levels, experienced:
-- Slower clinical decline compared to those on the Old Capsules and placebo.
-- A 40 percent lower incidence of worsening symptoms.
-- Significantly fewer falls (4 percent vs. 15.2 percent with Old Capsules and 19.7 percent with placebo).
Both the New and Old Capsules were well-tolerated, with no new safety concerns identified.
CervoMed plans to complete the full 32-week Extension phase in 2025 and engage with regulatory authorities to finalize plans for a Phase 3 trial.
These findings provide proof-of-concept for neflamapimod as a potential disease-modifying therapy for DLB, a condition with no currently approved treatments that slow disease progression.
Currently, CRVO is trading at $13.07 up by 31.76 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.